Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoji Watanabe

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Regenerative Therapy|February 2, 2019
Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)Michio Ozeki, Ryuta Asada, Akiko M Saito, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|March 26, 2025
Sirolimus treatment for intractable vascular anomalies (SIVA): An open-label, single-arm, multicenter, prospective trialMichio Ozeki, Saori Endo, Shiho Yasue, et al.
Frontiers in Medicine|February 23, 2024
Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trialMichio Ozeki, Saori Endo, Shiho Yasue, et al.
Japanese Journal of Radiology|March 25, 2020
Japanese clinical practice guidelines for vascular anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
The Journal of Dermatology|March 23, 2020
Japanese Clinical Practice Guidelines for Vascular Anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|March 24, 2020
Japanese clinical practice guidelines for vascular anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
Circulation|July 9, 2017
Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK SignalingMustapha Amyere, Nicole Revencu, Raphaël Helaers, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Regenerative Therapy|February 2, 2019
Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)Michio Ozeki, Ryuta Asada, Akiko M Saito, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|March 26, 2025
Sirolimus treatment for intractable vascular anomalies (SIVA): An open-label, single-arm, multicenter, prospective trialMichio Ozeki, Saori Endo, Shiho Yasue, et al.
Frontiers in Medicine|February 23, 2024
Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trialMichio Ozeki, Saori Endo, Shiho Yasue, et al.
Japanese Journal of Radiology|March 25, 2020
Japanese clinical practice guidelines for vascular anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
The Journal of Dermatology|March 23, 2020
Japanese Clinical Practice Guidelines for Vascular Anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|March 24, 2020
Japanese clinical practice guidelines for vascular anomalies 2017Hidefumi Mimura, Sadanori Akita, Akihiro Fujino, et al.
Circulation|July 9, 2017
Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK SignalingMustapha Amyere, Nicole Revencu, Raphaël Helaers, et al.
Pageof 8